PHASEBIO PHARMACEUTICALS

YTD

ALL

Why Robinhood?

You can watch PHASQ and buy or sell other stocks, ETFs, and their options commission-free!

About PHASQ

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension.

CEO

Jonathan P. Mow, MBA

CEOJonathan P. Mow, MBA

Employees

—

Employees—

Headquarters

Dover, Delaware

HeadquartersDover, Delaware

Founded

2002

Founded2002

Employees

—

Employees—

PHASQ Key Statistics

Market cap

—

Market cap—

Price-Earnings ratio

—

Price-Earnings ratio—

Dividend yield

—

Dividend yield—

Average volume

1.40

Average volume1.40

High today

—

High today—

Low today

—

Low today—

Open price

—

Open price—

Volume

0.00

Volume0.00

52 Week high

$0.001

52 Week high$0.001

52 Week low

—

52 Week low—

People also own

Based on the portfolios of people who own PHASQ. This list is generated using Robinhood data, and it’s not a recommendation.